Mesenchymal stem cells: Mechanisms of potential therapeutic benefit in ARDS and sepsis

James Walter, Lorraine B. Ware, Michael A. Matthay*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

112 Scopus citations

Abstract

Multipotent mesenchymal stem (stromal) cells (MSCs) have shown promising therapeutic effects in preclinical models of both acute respiratory distress syndrome (ARDS) and sepsis. Although initial research focused on the ability of MSCs to engraft at sites of tissue injury, increasing evidence suggests that MSCs have their therapeutic effects through mechanisms unrelated to long-term incorporation into host tissue. One of the most compelling of these pathways is the ability of MSCs to interact with injured tissue through the release of soluble bioactive factors. This Review provides an overview of the general properties of MSCs, and then outlines ways in which the paracrine effects of MSCs might reduce lung injury and enhance lung repair in ARDS and sepsis. Finally, we summarise ongoing challenges in MSC research and identify areas in which the discipline might progress in the coming years.

Original languageEnglish (US)
Pages (from-to)1016-1026
Number of pages11
JournalThe Lancet Respiratory Medicine
Volume2
Issue number12
DOIs
StatePublished - Dec 1 2014

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Mesenchymal stem cells: Mechanisms of potential therapeutic benefit in ARDS and sepsis'. Together they form a unique fingerprint.

Cite this